

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
16 November 2023 (16.11.2023)



(10) International Publication Number
WO 2023/220715 A1

(51) International Patent Classification:

C07D 209/34 (2006.01) A61P 11/00 (2006.01)
C07D 401/14 (2006.01) A61P 25/00 (2006.01)
C07D 403/12 (2006.01) A61P 29/00 (2006.01)
C07D 405/12 (2006.01) A61P 35/00 (2006.01)
A61P 9/00 (2006.01) A61K 31/404 (2006.01)

(21) International Application Number:

PCT/US2023/066934

(22) International Filing Date:

12 May 2023 (12.05.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/341,614 13 May 2022 (13.05.2022) US

(71) Applicant: **VENTUS THERAPEUTICS U.S., INC.**
[US/US]; 100 Beaver Street, Suite 201, Waltham, Massachusetts 02453 (US).

(72) Inventors; and

(71) Applicants: **DORICH, Stéphane** [CA/CA]; 124 avenue Pendennis, Pointe-Claire, Québec H9R 1H6 (CA). **ST-ONGE, Miguel** [CA/CA]; 1173 rue des Mesanges, Saint-Lazare, Québec J7T 2L5 (CA). **BURCH, Jason** [CA/CA]; 110 Boulevard Saint-Jean, Pointe-Claire, Québec H9S 4Z1 (CA). **BEVERIDGE, Ramsay** [CA/CA]; 73 Ave. Summerhill, Pointe-Claire, Québec H9R 2L3 (CA). **CIBLAT, Stéphane** [CA/CA]; 1260 rue Pauline-Julien, Montreal, Québec H2J 0A2 (CA). **CÔTÉ, Alexandre** [CA/CA]; 753 Boul. Union, Laval, Québec H7X 1X7 (CA). **CYR, Patrick** [CA/CA]; 67 rue Benoît, Saint-Constant, Québec J5A 0B2 (CA).

(74) Agent: **ERLACHER, Heidi** et al.; Cooley LLP, 1299 Pennsylvania Ave., Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with amended claims (Art. 19(1))

(54) Title: OXOINDOLINYL AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF

(57) Abstract: The present disclosure relates to compounds of Formula (I), or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, tautomer, isotopic derivative, prodrug or polymorph thereof. Further provided are pharmaceutical compositions comprising the same, methods of preparation, and methods of use and treatment, e.g., as inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein.



WO 2023/220715 A1